2,4-dimethoxy-3-nitropyridine | 18677-44-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2,4-dimethoxy-3-nitropyridine
• CAS: 18677-44-6
• 化学式: C₇H₈N₂O₄
• mdl: MFCD00971984
• 分子量: 184.152
• InChiKey: VCQKGKKVBWEFGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  77.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-dimethoxy-3-nitropyridine 在 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 2,4-二甲氧基-3-吡啶胺
  参考文献：
  名称：

  [EN] 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
  [FR] COMPOSÉS DE 7-AZAINDOLE POUR L'INHIBITION DE TYROSINE KINASES BCR-ABL

  摘要：

  本公开涉及抑制Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如慢性髓细胞白血病（CML）中的使用。

  公开号：

  WO2022076973A1
• 作为产物：
  描述：

  2,4-二氯-3-硝基吡啶 、 sodium methylate 以 甲醇 为溶剂， 反应 2.0h， 生成 2,4-dimethoxy-3-nitropyridine
  参考文献：
  名称：

  WO2020073011A5

  摘要：

  公开号：

  WO2020073011A5

文献信息

• [EN] 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES<br/>[FR] COMPOSÉS DE 7-AZAINDOLE POUR L'INHIBITION DE TYROSINE KINASES BCR-ABL
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022076973A1

  公开（公告）日：2022-04-14

  The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

  本公开涉及抑制Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如慢性髓细胞白血病（CML）中的使用。
• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
  申请人：Annapurna Bio Inc.

  公开号：EP3860998A1

  公开（公告）日：2021-08-11
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DU RÉCEPTEUR DE L'APJ
  申请人：ANNAPURNA BIO INC

  公开号：WO2020073011A1

  公开（公告）日：2020-04-09

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.
• WO2020073011A5
  申请人：——

  公开号：WO2020073011A5

  公开（公告）日：2022-10-12
• [EN] LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA LYSINE ACÉTYLTRANSFÉRASE 6A (KAT6A) ET LEURS UTILISATIONS
  申请人：[en]INSILICO MEDICINE IP LIMITED

  公开号：WO2023088233A1

  公开（公告）日：2023-05-25

  Described herein are KAT6A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KAT6A.